eCite Digital Repository
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension
Citation
Jing, ZC and Strange, G and Zhu, XY and Zhou, DX and Shen, JY and Gu, H and Yang, ZK and Pan, X and Xiang, MX and Yao, H and Zhao, DB and Dalton, BS and Zhang, ZL and Wang, Y and Chen, XS and Yang, YJ, Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension, The Journal of Heart and Lung Transplantation, 29, (2) pp. 150-156. ISSN 1053-2498 (2010) [Refereed Article]
DOI: doi:10.1016/j.healun.2009.09.020
Abstract
Background: Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population. Methods: We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean ± standard deviation age, 29.0 ± 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a change in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics. Results: At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 ± 0.6; p < 0.001), mean pulmonary artery pressure and pulmonary vascular resistance decreased (p < 0.01), and cardiac output increased (p < 0.001). Twelve patients (13%) experienced at least 1 adverse event. Conclusions: Bosentan improved exercise capacity, functional class, and cardiopulmonary hemodynamics in this patient cohort and was well tolerated. © 2010 International Society for Heart and Lung Transplantation.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Research Division: | Medical and Health Sciences |
| Research Group: | Cardiorespiratory Medicine and Haematology |
| Research Field: | Cardiology (incl. Cardiovascular Diseases) |
| Objective Division: | Health |
| Objective Group: | Clinical Health (Organs, Diseases and Abnormal Conditions) |
| Objective Field: | Cardiovascular System and Diseases |
| UTAS Author: | Dalton, BS (Mr Brad Dalton) |
| ID Code: | 65437 |
| Year Published: | 2010 |
| Web of Science® Times Cited: | 13 |
| Deposited By: | Health Sciences A |
| Deposited On: | 2010-11-16 |
| Last Modified: | 2011-04-05 |
| Downloads: | 0 |
Repository Staff Only: item control page